Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: FBR054
MIFTS: 44

Fibroma

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Fibroma

About this section

MalaCards integrated aliases for Fibroma:

Name: Fibroma 12 74 29 54 15 17

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0050871
Sources

Summaries for Fibroma

About this section
Disease Ontology : 12 A connective tissue benign neoplasm composed of fibrous or connective tissues that derives from mesenchymal tissue.

MalaCards based summary : Fibroma is related to chondromyxoid fibroma and ossifying fibroma. An important gene associated with Fibroma is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways is Striated Muscle Contraction. The drugs Pharmaceutical Solutions and Sorafenib have been mentioned in the context of this disorder. Affiliated tissues include bone, ovary and skin, and related phenotypes are Decreased cell migration and Decreased cell migration

Wikipedia : 74 Fibromas are benign tumors that are composed of fibrous or connective tissue. They can grow in all... more...

Sources

Related Diseases for Fibroma

About this section

Diseases related to Fibroma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 742)
# Related Disease Score Top Affiliating Genes
1 chondromyxoid fibroma 34.5 VIM S100A1 DES ACTC1
2 ossifying fibroma 34.4 USP6 SERPINA3 NF1 CDC73
3 liver fibroma 34.0 VIM CALB2
4 testicular fibroma 33.8 CD34 CALB2
5 basal cell nevus syndrome 33.2 PTCH1 NF1 CTNNB1
6 fibromatosis 33.2 VIM DES CTNNB1 ACTC1
7 skin tag 33.1 SERPINA3 PTCH1 CD34
8 pyogenic granuloma 33.0 CD34 ACTC1
9 cutaneous fibrous histiocytoma 31.7 VIM SERPINA3 S100A1 F13A1 DES CD68
10 rare tumor 31.6 DES ACTC1
11 pleomorphic lipoma 31.0 SERPINA3 CD68 CD34
12 fibrosarcoma 31.0 VIM MALAT1 DES ACTC1
13 desmoid tumor 30.9 DES CTNNB1 CD34 ACTC1
14 infantile digital fibromatosis 30.9 VIM DES
15 epulis 30.8 VIM SERPINA3 DES CD68
16 exophthalmos 30.8 NF1 FLNA CD68 CD34
17 chondroma 30.8 S100A1 NF1 CTNNB1 ACTC1
18 lipomatosis, multiple 30.7 SERPINA3 NF1 DES CD34
19 odontogenic myxoma 30.7 VIM SERPINA3
20 perineurioma 30.7 VIM S100A1 ACTC1
21 fasciitis 30.7 VIM USP6 CD34 ACTC1
22 spindle cell sarcoma 30.6 VIM SERPINA3 DES CD34 ACTC1
23 ameloblastoma 30.6 SERPINA3 PTCH1 CTNNB1 CALB2
24 leiomyoma 30.6 VIM S100A1 PTCH1 DES CD34 ACTC1
25 benign mesothelioma 30.5 CD34 CALB2
26 chordoma 30.5 VIM SERPINA3 S100A1 DES CTNNB1
27 sarcoma 30.5 VIM SERPINA3 S100A1 DES CTNNB1 ACTC1
28 mesenchymal cell neoplasm 30.5 SERPINA3 CD68 CD34
29 nodular tenosynovitis 30.5 SERPINA3 S100A9
30 erythema elevatum diutinum 30.4 S100A9 F13A1 CD34
31 basal cell carcinoma 30.4 PTCH1 IVL CTNNB1 CD68 CD34
32 ovarian fibrothecoma 30.4 DES CALB2 ACTC1
33 cystadenoma 30.3 SERPINA3 MUC16 CALB2
34 giant cell reparative granuloma 30.3 USP6 SERPINA3 NF1 CD68
35 congenital epulis 30.3 VIM SERPINA3 DES CD68
36 intestinal obstruction 30.3 SERPINA3 FLNA CD34
37 myofibroma 30.3 SERPINA3 S100A1 F13A1 DES CD34
38 myoblastoma 30.3 CD68 CALB2
39 neurofibroma 30.3 VIM S100A1 NF1 F13A1 CD34 ACTC1
40 cutaneous leiomyosarcoma 30.2 VIM DES ACTC1
41 neuroma 30.2 SERPINA3 NF1 CD68 CD34
42 chondroid chordoma 30.2 VIM SERPINA3 S100A1
43 pseudo-meigs syndrome 30.2 MUC16 CALB2
44 verruciform xanthoma of skin 30.1 SERPINA3 CD68
45 hemangioma 30.1 CTNNB1 CD68 CD34 ACTC1
46 dermatofibrosarcoma protuberans 30.1 VIM SERPINA3 S100A1 F13A1 DES CD34
47 teratoma 30.1 VIM CTNNB1 CALB2 ACTC1
48 meningioma, familial 30.1 SERPINA3 PTCH1 NF1 CTNNB1 CD68 CD34
49 spindle cell lipoma 30.1 VIM S100A9 DES CD34 ACTC1
50 myxofibrosarcoma 30.1 SERPINA3 DES CD34

Graphical network of the top 20 diseases related to Fibroma:



Diseases related to Fibroma
Sources

Symptoms & Phenotypes for Fibroma

About this section

GenomeRNAi Phenotypes related to Fibroma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 8.8 TSC1 VIM
2 Decreased cell migration GR00055-A-3 8.8 FLNA

MGI Mouse Phenotypes related to Fibroma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.06 ACTC1 CDC73 CTNNB1 DES F13A1 FLNA
2 cellular MP:0005384 10.03 ACTC1 CD34 CDC73 CTNNB1 DES FLNA
3 homeostasis/metabolism MP:0005376 10 ACTC1 CD34 CDC73 CTNNB1 DES F13A1
4 muscle MP:0005369 9.61 ACTC1 CDC73 CTNNB1 DES NF1 PTCH1
5 respiratory system MP:0005388 9.28 CDC73 CTNNB1 F13A1 FLNA NF1 PTCH1
Sources

Drugs & Therapeutics for Fibroma

About this section

Drugs for Fibroma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Pharmaceutical Solutions Phase 4
2
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
3 Protein Kinase Inhibitors Phase 3
4
Toremifene Approved, Investigational Phase 2 89778-26-7 3005573
5
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
6
Denosumab Approved Phase 2 615258-40-7
7
Ipilimumab Approved Phase 2 477202-00-9
8
nivolumab Approved Phase 2 946414-94-4
9
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
10
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
11
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
12
Guaifenesin Approved, Investigational, Vet_approved Phase 2 93-14-1 3516
13
Imidazole Experimental, Investigational Phase 2 288-32-4 795
14 Estrogens Phase 2
15 Estrogen Receptor Modulators Phase 2
16 Vaccines Phase 2
17 Imatinib Mesylate Phase 2 220127-57-1 123596
18
Liposomal doxorubicin Phase 2 31703
19 Immunoglobulins Phase 2
20 Antibodies Phase 2
21 Antibodies, Monoclonal Phase 2
22 Antineoplastic Agents, Immunological Phase 2
23 Anti-Infective Agents Phase 1, Phase 2
24 Immunologic Factors Phase 1, Phase 2
25 Immunosuppressive Agents Phase 1, Phase 2
26 Antifungal Agents Phase 1, Phase 2
27 Anti-Bacterial Agents Phase 1, Phase 2
28 Antibiotics, Antitubercular Phase 1, Phase 2
29 Chlorpheniramine, phenylpropanolamine drug combination Phase 2
30
Triamcinolone Approved, Vet_approved Phase 1 124-94-7 31307
31 Hormone Antagonists Phase 1
32 Hormones Phase 1
33 glucocorticoids Phase 1
34 triamcinolone acetonide Phase 1
35 Triamcinolone diacetate Phase 1
36 Triamcinolone hexacetonide Phase 1
37 Anti-Inflammatory Agents Phase 1
38
Heparin Approved, Investigational 9005-49-6 46507594 772
39
Nadroparin Approved, Investigational
40
tannic acid Approved 1401-55-4
41
Benzocaine Approved, Investigational 94-09-7, 1994-09-7 2337
42
Chlorhexidine Approved, Vet_approved 55-56-1 9552079 2713
43
Iodine Approved, Investigational 7553-56-2 807
44
silver nitrate Approved, Investigational 7761-88-8
45
Povidone-iodine Approved 25655-41-8
46
Povidone Approved 9003-39-8
47
Ethanol Approved 64-17-5 702
48
Cetrorelix Approved, Investigational 120287-85-6 16129715 25074887
49
Ganirelix Approved 123246-29-7, 124904-93-4 25081094
50
Menotropins Approved 61489-71-2, 9002-68-0 5360545

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Prevadhâ„¢ in the Prevention of Adhesions in Gynaecological Surgery: a Multicenter, Randomized, French Study Completed NCT01388907 Phase 4
2 Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction Recruiting NCT02228889 Phase 4
3 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF) Recruiting NCT03785964 Phase 3 Nirogacestat oral tablet;Placebo Oral Tablet
4 Single Blinded Randomized Study of Volume Reduction of Uterine Fibroids After Uterine Artery Embolization Versus Computer Tomography or Ultrasound Guided Percutaneous Microwave Ablation Evaluated by Magnetic Resonance Imaging Recruiting NCT02942537 Phase 2, Phase 3
5 A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF) Active, not recruiting NCT02066181 Phase 3 Sorafenib Tosylate
6 Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets Unknown status NCT02353429 Phase 2 Toremifene
7 Open Label Phase II Clinical Trial of Myoma Immunotherapy Unknown status NCT03550703 Phase 2
8 Phase II Study to Evaluate Glivec (Imatinib Mesylate) to Induce Progression Arrest in Aggressive Fibromatosis / Desmoid Tumors Not Amenable to Surgical Resection With R0 Intent or Accompanied by Unacceptable Function Loss Completed NCT01137916 Phase 2 Imatinib
9 A Phase II Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis) Completed NCT02495519 Phase 2 Imatinib
10 Phase II Pilot Study Of Moderate Dose Radiotherapy For Inoperable Aggressive Fibromatoses Completed NCT00030680 Phase 2
11 A Phase 2, Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids Completed NCT02323646 Phase 2 Placebo;Telapristone Acetate
12 Multicentric Phase I/II Study Evaluating the Efficacy and Toxicity of Imatinib in Adult Patients With Aggressive Fibromatosis That Cannot be Treated by Surgery or Curative Radiotherapy Completed NCT00287846 Phase 1, Phase 2 imatinib mesylate
13 Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis Recruiting NCT03966742 Phase 2
14 Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label Recruiting NCT03363763 Phase 2 Sirolimus 0.2%;Sirolimus 0.4%;Placebo ointment
15 An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects With Giant Cell Rich Tumors of Bone Recruiting NCT03605199 Phase 2 Denosumab
16 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
17 A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis Active, not recruiting NCT01265030 Phase 1, Phase 2 Sirolimus
18 Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis Active, not recruiting NCT01981551 Phase 2 PF-03084014
19 A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors Not yet recruiting NCT04195399 Phase 2 Nirogacestat
20 Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors in Adults and Children (CHP-914) Withdrawn NCT00978146 Phase 2 Hydroxyurea
21 A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors Active, not recruiting NCT03627741 Phase 1 Triamcinolone Acetonide
22 Free Radical Level in SCC of Tongue Patients Tumor, Serum and Saliva Unknown status NCT00426062
23 Operative Hysteroscopy for Fibroma by Classic Resection Versus Morcellation: a Ramdomised Study Unknown status NCT02406898
24 Clinicopathological and Molecular Correlation of Acrochordon in Relation to Human Papillomavirus Infection Unknown status NCT00520078
25 Peripheral Primitive Fibromatosis. Study Evaluating a Simple Initial Monitoring With Search of Scalability Predictive Factors and Registration of Treatments in Case of Progression Unknown status NCT01801176
26 3-dimensional Versus Conventional Laparoscopy in Patients Undergoing Total Hysterectomy for Benign Disease - A Randomised Clinical Trial Unknown status NCT02610985
27 Role of Doppler Ultrasound in Evaluation of Superficial Soft Tissue Masses Unknown status NCT03171857
28 A Comparison of Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy. Unknown status NCT01289314
29 Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients Unknown status NCT02547831
30 Interventional Study to Determine the Effectiveness of Medium Intensity Verses Low Intensity Tobacco Use Prevention and Cessation Intervention in the Unorganized Sector of Zari Workers in Mumbai Unknown status NCT02103868
31 Studio Pilota Farmacocinetico-clinico Sulla Somministrazione di Eparina a Basso Peso Molecolare e Dosaggio Sierico di HGF Nelle Pazienti Operate Affette da Patologie Ginecologiche Completed NCT01523652
32 Sentinel Lymph Node Biopsy in Porocarcinoma: A Case Reports Completed NCT03647631
33 A Prospective Analysis of Active Observation in Patients With Desmoid-Type Fibromatosis Recruiting NCT04281381
34 Biomarkers for Tuberous Sclerosis Complex: An International Multicenter Observational Longitudinal Protocol Recruiting NCT02654340
35 The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study Recruiting NCT02402244
36 National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis Recruiting NCT02867033
37 Comparative Study in the Clinical Efficacy, Satisfaction and Complications While Treating Walking Spica Cast vs Synthetic Pants in the Management of Pediatric Low-energy Femoral Shaft Fracture. Randomized Clinical Trial Recruiting NCT04311866
38 Randomized Clinical Trial on Traditional Healing Versus Moist Healing Environment (MHE) Applied to Minor Surgery in the Exeresis of Skin Tags Recruiting NCT04161274
39 Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Women With Infertility Problems Recruiting NCT04071574 Human Chorionic Gonadotropin (hCG);Gonadotropins;GNRH-A Triptorelin;GnRH antagonist
40 Biomarker for Hyaline Fibromatosis Syndrome - An International, Multicenter, Epidemiological Protocol Active, not recruiting NCT03196115
41 A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol Active, not recruiting NCT00919269
42 The Evaluation of Health-related Quality of Life Issues Experienced by Patients With Desmoid-type Fibromatosis Enrolling by invitation NCT04289077
43 Diagnostic Performances of Preoperative Echo-guided Uterine Biopsy in the Management of Suspect Uterine Sarcoma Tumors Not yet recruiting NCT04250766
44 Pilot Investigation of 18F-FES PET/CT Imaging of Desmoid Tumors Terminated NCT02374931 Early Phase 1 F-18 16 Alpha-Fluoroestradiol
45 South Miami Hospital Fibroid Registry Terminated NCT02362009
46 Observational Prospective Study on Patients With Symptomatic Uterine Fibroids Treated With VizAblate® Intrauterine-ultrasound Guided RF Ablation Terminated NCT01998854

Search NIH Clinical Center for Fibroma

Sources

Genetic Tests for Fibroma

About this section

Genetic tests related to Fibroma:

# Genetic test Affiliating Genes
1 Fibroma 29
Sources

Anatomical Context for Fibroma

About this section

MalaCards organs/tissues related to Fibroma:

40
Bone, Ovary, Skin, Heart, Breast, Lung, Uterus
Sources

Publications for Fibroma

About this section

Articles related to Fibroma:

(show top 50) (show all 6955)
# Title Authors PMID Year
1
Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. 54 61
19033865 2009
2
Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas. 61 54
18292222 2008
3
Loss of the PTCH1 gene locus in cardiac fibroma. 61 54
18329553 2008
4
Is loss of heterozygosity at 9q22.3 (PTCH gene) and 19p13.3 (STK11 gene) involved in the pathogenesis of ovarian stromal tumors? 61 54
16084949 2005
5
Role of the hedgehog/patched signaling pathway in oncogenesis: a new polymorphism in the PTCH gene in ovarian fibroma. 61 54
15659790 2004
6
Origin of stellate giant cells in oral fibrous lesions determined by immunohistochemical expression of vimentin, HHF-35, CD68 and factor XIIIa. 54 61
15370129 2004
7
Solitary sclerotic fibroma of skin: a possible link with pleomorphic fibroma with immunophenotypic expression for O13 (CD99) and CD34. 61 54
14744088 2003
8
Ultrastructural and immunohistochemical characterization of the so-called giant multinucleate cells in cutaneous collagenomas. 61 54
12147091 2002
9
Fibroma and inflammatory myofibroblastic tumor of the heart. 54 61
11745071 2001
10
S100A6 expression in fibrohistiocytic lesions. 54 61
11401666 2001
11
Two cases of supernumerary ovary: one with large fibroma with Meig's syndrome and the other with endometriosis and cystic change. 61 54
11795834 2001
12
Cytokeratin expression in trichoblastic fibroma (small nodular type trichoblastoma), trichoepithelioma and basal cell carcinoma. 54 61
10215762 1999
13
Benign fibromatous tumors of the testis and paratesticular region: a report of 9 cases with a proposed classification of fibromatous tumors and tumor-like lesions. 54 61
9060599 1997
14
Pleomorphic hamartoma of the subcutis: a lesion with possible myogenous and neural lineages. 61 54
7593822 1995
15
An immunohistochemical study of odontogenic mixed tumours. 61 54
7543314 1995
16
Phenotypic characterisation of stellate and giant cells in giant cell fibroma by immunocytochemistry. 54 61
7523665 1994
17
So-called "immature dentinoma": a case presentation and histological comparison with ameloblastic fibrodentinoma. 61 54
8164161 1994
18
Histologic and immunohistochemical evidence for considering ovarian myxoma as a variant of the thecoma-fibroma group of ovarian stromal tumors. 54 61
7688213 1993
19
Mesothelial and related neoplasms in children and adolescents: a clinicopathologic and immunohistochemical analysis of eight cases. 54 61
1384016 1992
20
Cytoskeletal gene expression in normal and neoplastic human odontogenic epithelia. 54 61
1721670 1991
21
Immunohistochemical analysis for desmin in normal and neoplastic ovarian stromal tissue. 61 54
2159271 1990
22
Primary ovarian leiomyoma: Imaging in a rare entity. 61
32461778 2020
23
Limb anomalies, microcephaly, dysmorphic facial features and fibroma of the tongue after failed abortion with methotrexate and misoprostol. 61
32541333 2020
24
Cutaneous "fibroma-like" perivascular epithelioid cell tumor: A case report and review of literature. 61
31943330 2020
25
Secondary aneurysmal bone cysts and associated primary lesions: imaging features of 49 cases. 61
32036238 2020
26
[Tumor-like bony lesions of the skeleton]. 61
32556370 2020
27
Solitary Sclerotic Fibroma: Dermoscopic Features. 61
32531243 2020
28
Calcifying aponeurotic fibroma around Achilles tendon: A case report. 61
32300471 2020
29
Ossifying fibroma arising from the zygomatic arch: A case report. 61
31476540 2020
30
Delayed Infection of Porous Polyethylene Implants After Oncologic Maxillectomy and Reconstruction: 2 Case Reports and Review of Literature. 61
32538671 2020
31
Increased Prostate-Specific Membrane Antigen Uptake in Neurofibromatosis. 61
32332318 2020
32
Endoscopic Optic Nerve Decompression for Optic Neuropathy in Sinonasal Fibro-Osseous Tumors. 61
32105872 2020
33
A Multicenter Study of Tongue Lesions from Thailand. 61
32542633 2020
34
Chondromyxoid Fibroma of the Sacral Spine. 61
32362154 2020
35
Pseudo-Meigs Syndrome Caused by a Giant Uterine Leiomyoma with Cystic Degeneration: A Case Report. 61
31902853 2020
36
Ovarian Fibroma With Bizarre Nuclei: A Rare Finding. 61
32390474 2020
37
Pancreatic Fibroma: A Rare Cause of Intraperitoneal Hemorrhage. 61
32466855 2020
38
Large Left Ventricular Fibroma: Case Report and Literature Review. 61
32362236 2020
39
Oral Fibroma Removal With a Er,Cr:YSSG Laser. 61
32369382 2020
40
Intraoral Approach for Surgical Treatment of Psammomatoid Juvenile Ossifying Fibroma. 61
31934971 2020
41
Ossifying Fibroma of The Cervical Spine: The First Case Report and Literature Review. 61
32437986 2020
42
Simultaneous presentation of juvenile ossifying fibroma in the maxilla and mandible: a case report. 61
32480339 2020
43
Ocular Surface Fibroma: Clinical, Histopathological, and Immunohistochemical Features of 10 Cases. 61
32509765 2020
44
Successful surgical treatment of cardiac metastasis from uterine leiomyosarcoma: A case report and literature review. 61
32166826 2020
45
Jaffe-Campanacci syndrome or neurofibromatosis type 1: a case report of phenotypic overlap with detection of NF1 gene mutation in non-ossifying fibroma. 61
32393377 2020
46
Ameloblastic fibrosarcoma: clinicopathological and molecular analysis of seven cases highlighting frequent BRAF and occasional NRAS mutations. 61
31899815 2020
47
Onychomatricoma Presenting as a Dystrophic Right Great Toenail: Case Report and Review. 61
32499986 2020
48
Genetic testing for hereditary hyperparathyroidism and familial hypocalciuric hypercalcaemia in a large UK cohort. 61
32430905 2020
49
The Unusual Case of Fibroma of Tendon Sheath in a Young Girl with Turner Syndrome Undergoing Growth Hormone Treatment. 61
32349463 2020
50
A Non-ossifying Fibroma and a Stress Fracture of the Femur Mimicking Bone Malignancy in a Child. 61
32411553 2020
Sources

Variations for Fibroma

About this section
Sources

Expression for Fibroma

About this section
Search GEO for disease gene expression data for Fibroma.
Sources

Pathways for Fibroma

About this section

Pathways related to Fibroma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Striated Muscle Contraction 65 1
10.66 VIM DES ACTC1
Sources

GO Terms for Fibroma

About this section

Cellular components related to Fibroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.21 VIM USP6 TSC1 S100A9 S100A1 NF1
2 cytoskeleton GO:0005856 9.8 VIM TSC1 S100A9 FLNA DES CTNNB1
3 extracellular exosome GO:0070062 9.61 VIM SERPINA3 S100A9 MUC16 IVL FLNA
4 actin filament GO:0005884 9.5 TSC1 FLNA ACTC1
5 fascia adherens GO:0005916 9.16 DES CTNNB1
6 Z disc GO:0030018 8.92 S100A1 FLNA DES CTNNB1

Biological processes related to Fibroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell-matrix adhesion GO:0007160 9.61 TSC1 CTNNB1 CD34
2 negative regulation of cell proliferation GO:0008285 9.55 TSC1 PTCH1 NF1 CTNNB1 CDC73
3 regulation of long-term synaptic potentiation GO:1900271 9.46 NF1 CALB2
4 cerebral cortex development GO:0021987 9.43 TSC1 NF1 FLNA
5 smooth muscle tissue development GO:0048745 9.4 PTCH1 NF1
6 negative regulation of oligodendrocyte differentiation GO:0048715 9.37 NF1 CTNNB1
7 regulation of cell-matrix adhesion GO:0001952 9.32 TSC1 NF1
8 endodermal cell fate commitment GO:0001711 8.96 CTNNB1 CDC73
9 muscle filament sliding GO:0030049 8.8 VIM DES ACTC1
Sources

Sources for Fibroma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....